

## Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

bcl2fastq 2.20.0.422

Data analysis

Bowtie 2.2.9; STAR 2.5.3a; RSEM 1.3.1; R 3.3.2; ngsplot 2.61; Homer 4.9.1

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

GEO GSE124375

### Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	<input type="text" value="No specific methods were used for sample size estimation"/>
Data exclusions	<input type="text" value="No data were excluded"/>
Replication	<input type="text" value="All conclusions were replicated"/>
Randomization	<input type="text" value="No randomization was used"/>
Blinding	<input type="text" value="No blinding was used"/>

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data

### Methods

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Antibodies

Antibodies used	<input type="text" value="anti-pol2, Cell Signaling, 14958, Rbp1 NTD (D8L4Y)   anti-Chd2, Millipore, MABE873, clone 8H3, lot: 2991839   anti-beta tubulin, Sigma, T4026, clone TUB 2.1, lot: 043M4785"/>
Validation	<input 8h3="" anti-beta="" anti-chd2="" antibody="" antibody,="" been="" blot"="" blotting\"="" clone="" distributor="" for="" from="" has="" in="" is="" this="" tubulin:="" type="text" use="" validated="" value="For anti-pol2, which was used for ChIP, from distributor website: For optimal ChIP and ChIP-seq results, use 10 µl of antibody and 10 µg of chromatin (approximately 4 x 10^6 cells) per IP. This antibody has been validated using SimpleChIP® Enzymatic Chromatin IP Kits. For anti-Chd2: From distributor website: \" website:="" western=""/>

## Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)	<input type="text" value="R1 mESCs from Nagy lab, all other lines from ATCC"/>
Authentication	<input type="text" value="Cell lines used were not authenticated"/>
Mycoplasma contamination	<input type="text" value="We confirm that all cells were tested for mycoplasma, and found negative"/>
Commonly misidentified lines (See <a href="#">ICLAC</a> register)	<input type="text" value="No commonly misidentified cell lines were used"/>

## Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

Laboratory animals	<input type="text" value="Mice founders were generated using CB6F1 and backcrossed with C57BL/6. Study was conducted and males and females interchangeably from E9.5 to 16 week old mice."/>
--------------------	--

Wild animals	This study did not involve wild animals
Field-collected samples	N/A
Ethics oversight	Weizmann Institutional Animal Care and Use Committee (IACUC)

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## ChIP-seq

### Data deposition

- Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).
- Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links <i>May remain private before publication.</i>	GEO GSE124375
Files in database submission	bigWigCoverage files and raw FASTQ datano peak calling was performed
Genome browser session (e.g. <a href="#">UCSC</a> )	bigWig tracks are available in the GEO submission

### Methodology

Replicates	2 replicates for each condition in mEFs
Sequencing depth	At least 1C million reads per replicate
Antibodies	anti-pol2, Cell Signaling, 14958, Rbp1 NTD (D8L4Y)
Peak calling parameters	No peak calling was used for ChIP-seq data
Data quality	bigWig visual inspection
Software	Bowtie2 for read mapping, Homer for read counting